Taken together, all our findings elucidated that FOXA2 suppression by TRIM36 represents a potential therapeutic strategy for CRC treatment by inducing ferroptosis via withholding Nrf2/GPX4 signaling pathway. Here, FOXA2 is linked to colorectal carcinoma.